Alyeska Investment Group L.P. Raises Position in Insmed Incorporated (NASDAQ:INSM)

Alyeska Investment Group L.P. grew its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 25.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 935,779 shares of the biopharmaceutical company's stock after purchasing an additional 188,377 shares during the period. Alyeska Investment Group L.P. owned about 0.52% of Insmed worth $64,606,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management acquired a new position in Insmed during the 4th quarter valued at about $47,000. Smartleaf Asset Management LLC raised its position in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed during the 4th quarter valued at approximately $86,000.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 6,830 shares of the business's stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. The trade was a 2.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sara Bonstein sold 28,390 shares of the firm's stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,296,751.00. Following the completion of the transaction, the chief financial officer now directly owns 155,506 shares of the company's stock, valued at $12,580,435.40. The trade was a 15.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 368,737 shares of company stock valued at $29,364,317. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Performance

Shares of INSM stock traded up $0.41 during midday trading on Wednesday, hitting $68.28. The company had a trading volume of 1,875,367 shares, compared to its average volume of 2,318,244. The stock has a market cap of $12.41 billion, a price-to-earnings ratio of -12.21 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company's 50 day simple moving average is $73.09 and its 200 day simple moving average is $73.40. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of research reports. Wells Fargo & Company increased their price objective on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Guggenheim reaffirmed a "buy" rating and issued a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. JPMorgan Chase & Co. lifted their price target on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.